logo
ENTITY

Sunesis Pharmaceuticals (SNSS US)

14
Analysis
Health Care • United States
Sunesis Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The company's primary activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Sunesis Pharmaceuticals was founded on February 10, 1998 and is headquartered in South San Francisco, CA.
more
bullish•Sunesis Pharmaceuticals
•03 Aug 2017 18:00•Issuer-paid

SNS-062 trial up and running

Sunesis announced on 18 July 2017 that the first patient had been dosed in its Phase Ib/II study of SNS-062 for the treatment of chronic...

Logo
Share
bullish•Sunesis Pharmaceuticals
•10 May 2017 18:41•Issuer-paid

Redirection after EMA application pulled

Sunesis reported in May 2017 that it has pulled its application to the EMA for the approval of vosaroxin for the treatment of acute myeloid...

Logo
Share
bullish•Sunesis Pharmaceuticals
•15 Mar 2017 17:12•Issuer-paid

Getting closer to EU approval

The company’s application for EU approval for vosaroxin approval in AML continues to progress. The company will go before the Oncology Division of...

Logo
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3

x